Holen Sie sich die Stockscreener-App
28.18
2.99%
-0.87
Handel nachbörslich:
28.21
0.03
+0.11%
Schlusskurs vom Vortag:
$29.05
Offen:
$28.67
24-Stunden-Volumen:
967.35K
Relative Volume:
0.95
Marktkapitalisierung:
$2.13B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.16M
KGV:
-22.19
EPS:
-1.2702
Netto-Cashflow:
$-69.06M
1W Leistung:
+0.75%
1M Leistung:
+63.84%
6M Leistung:
-23.69%
1J Leistung:
-22.30%
1-Tages-Spanne:
$28.09
$28.76
1-Wochen-Bereich:
$26.00
$30.23
52-Wochen-Spanne:
$14.80
$40.47
Cg Oncology Inc Stock (CGON) Company Profile
Firmenname
Cg Oncology Inc
Sektor
Branche
Telefon
(949) 419-6203
Adresse
400 SPECTRUM CENTER DRIVE, IRVINE
Vergleichen Sie CGON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
28.18 | 2.13B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2024-06-28 | Eingeleitet | BofA Securities | Buy |
| 2024-02-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Eingeleitet | Goldman | Neutral |
| 2024-02-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
CG Oncology Jumps 25% on Positive Trial Results - Orange County Business Journal
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of “Buy” by Analysts - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Invesco Ltd. - Defense World
CG Oncology initiated with an Overweight at JPMorgan - TipRanks
CGON Stock: JP Morgan Initiates Coverage with Overweight Rating - GuruFocus
JPMorgan Initiates Coverage on CG Oncology With Overweight Rating, $41 Price Target - marketscreener.com
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Ta - GuruFocus
CG Oncology (NASDAQ:CGON) Reaches New 1-Year Low After Insider Selling - Defense World
Why CG Oncology, Inc. (CGON) Surged on Monday - MSN
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Cg Oncology Inc’s (CGON) Stock Is Harder To Predict Than You Think - Stocksregister
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Wells Fargo & Company MN - Defense World
A look into Cg Oncology Inc (CGON)’s deeper side - Sete News
Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX
Could Cg Oncology Inc (NASDAQ: CGON) Be The Biggest Winner? - Marketing Sentinel
Barclays PLC Acquires 10,737 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology's Bladder Cancer Drug Impresses InvestorsHere's Why - AOL.com
Cg Oncology Inc [CGON] Stock sold by Insider POST LEONARD E for $28000.0 - knoxdaily.com
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? - MSN
TD Cowen Sticks to Its Buy Rating for CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Given Overweight Rating at Cantor Fitzgerald - Defense World
CG Oncology’s (CGON) Buy Rating Reaffirmed at HC Wainwright - Defense World
CG Oncology shares jump on positive clinical trial data for cancer drug - Mugglehead Magazine
CG Oncology Stock (CGON) Surges 25% As Cancer Drug Shows Remarkable Results - TipRanks
J&J Looks To Overcome Drug-Delivery Limitations In Bladder Cancer With TAR-200 - insights.citeline.com
CG Oncology (CGON) Surges 25%: What Drove the Dramatic Stock Move? - Wealth Daily
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga
CG Oncology’s Blistering Rally: What You Need to Know - RagingBull
Cantor Fitzgerald maintains CG Oncology stock with $75 target - Investing.com Australia
CG Oncology Reports Durable Responses for Cretostimogene in Bladder Cancer Treatment; Shares Rise - marketscreener.com
Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe - Endpoints News
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug - inkl
This Small Biotech Rival To J&J Just Rocketed 44% - Investor's Business Daily
Cantor Fitzgerald maintains CG Oncology stock with $75 target By Investing.com - Investing.com India
Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings - Benzinga
Cg Oncology Inc (CGON) did well last session? - uspostnews.com
CG Oncology (CGON) Announces Phase 3 Trial Results Discussion - GuruFocus
Contrasting CG Oncology (CGON) & Its Rivals - Defense World
CGON Shows Promising Results in Bladder Cancer Study | CGON Stoc - GuruFocus
CGON: Insights on Phase 3 BOND-003 Trial Results for Bladder Can - GuruFocus
CG Oncology announces Phase 3 BOND-003 data presented at AUA meeting - TipRanks
CG Oncology Reports Promising 24-Month Efficacy and Safety Data for Cretostimogene Monotherapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq
CG Oncology Announces Best-In-Disease Durability Data In Bond-003 Cohort C & Promising Early Signal In Cohort P For Cretostimogene Grenadenorepvec - TradingView
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting - The Globe and Mail
CG Oncology Bladder Cancer Drug Shows 42% Complete Response at 24 Months | CGON Stock News - Stock Titan
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025 - The Manila Times
CG Oncology's Breakthrough Phase 3 Bladder Cancer Treatment Data: What The AUA Plenary Will Reveal - Stock Titan
Daily Market Movement: Cg Oncology Inc (CGON) Sees a 0.34 Increase, Closing at 20.48 - DWinneX
Taking a Closer Look At Cg Oncology Inc (CGON) Following Its Recent Trade - knoxdaily.com
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates - ADVFN
Finanzdaten der Cg Oncology Inc-Aktie (CGON)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):